• ABPI Website
  • Media
  • ABPI response to UKHSA Vaccine Development and Evaluation Centre (VDEC) announcement

ABPI response to UKHSA Vaccine Development and Evaluation Centre (VDEC) announcement

The UKHSA has announced the opening of its Vaccine Development and Evaluation Centre (VDEC). 

Commenting on the opening, Janet Valentine, ABPI Executive Director, Innovation and Research Policy said:

“The COVID-19 pandemic taught us that through extraordinary interventions and public sacrifice we could slow down the spread of the virus, but not stop infection, and this came with huge economic and personal cost. But the most important lesson learnt is that the only way to beat a pandemic is by actively seeking and delivering new vaccines and treatments, the sooner, the better. 

“This new research centre is an essential national asset, which in partnership with industry, strengthens the UK’s pandemic defences, and takes us closer to our shared 100 Days Mission target to beating any new virus or pathogen.”

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.